News | August 25, 2011

Radiation Therapy Oncology Group Awards US Oncology Research Full Member Status

August 25, 2011 — US Oncology Research (USOR) and Radiation Therapy Oncology Group (RTOG) announced that USOR has earned Full Member status. As a Full Member, USOR has proven to be a leader in radiation clinical trials. The organization is one of fewer than 50 to reach this status.

Since becoming an Affiliate Member of RTOG in 2008, USOR quickly became one of the top accruing members. Its network of oncology practices eventually enrolled more patients in RTOG trials than any other member. In 2010, RTOG announced USOR ranked number one in patient accruals, surpassing all affiliate and full RTOG members.

All together, network physicians have enrolled 163 patients into RTOG clinical trials held at community-based oncology practices. This allows patients to receive cutting-edge radiation clinical trials in their hometowns.

"US Oncology Research has been an outstanding Affiliate Member, and we're excited to award the network Full Member status. We at RTOG are very pleased that US Oncology Research achieved full member status as quickly as they did," said Walter J Curran, Jr., M.D., chairman, RTOG group chairman and executive director of the Winship Cancer Institute of Emory University. "Their commitment to providing the infrastructure to accrue large numbers of patients into clinical trial research from community-based practices will not only benefit their patients, it will also help us answer our research questions faster, and that will benefit all cancer patients."

Radiation oncology-focused clinical trials offer cancer patients integrated and unique therapies that can provide a better chance for survival. Clinical trials in cancer care, whether focused on chemotherapy, radiation or other treatment methods, seek improvement upon standard treatment, so each patient has the best opportunity for a positive outcome.

"We are making great strides in a concentration that is quite unique," said Vivek Kavadi, M.D., medical director of radiation oncology for US Oncology and radiation oncologist with Texas Oncology-Sugar Land. "Having radiation oncology clinical trials available in local communities is crucial for our patients. They are able to participate in integrated, radiation-focused clinical trials that are truly state-of-the-art."

There are 19 RTOG approved sites affiliated with USOR. These community-based practices are located across the country and had 91 accruals in 2010. USOR averages eight accruals per month.

In order to remain an RTOG Full Member, the membership evaluation committee, according to the RTOG membership evaluation policy and the group bylaws, must evaluate USOR yearly.

Based in Philadelphia, RTOG is a key clinical research component of the American College of Radiology (ACR) and serves as a multi-institutional, international clinical cooperative group funded primarily by the National Cancer Institute (NCI).

For more information: or

Related Content

MRI Reveals Striking Brain Differences in People with Genetic Autism

Example images for a control participant , a deletion carrier, and a duplication carrier. In the sagittal image of the deletion carrier, the thick corpus callosum, dens and craniocervical abnormality, and cerebellar ectopia are shown. For the duplication carrier, the sagittal image shows the thin corpus callosum and the axial image shows the increased ventricle size and decreased white matter volume. Image courtesy of the Radiological Society of North America (RSNA).

News | Neuro Imaging | August 09, 2017
August 9, 2017 — In the first major study of its kind, researchers using magnetic...
Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
brain with chronic traumatic injury
News | Magnetic Resonance Imaging (MRI) | August 02, 2017
Fighters are exposed to repeated mild traumatic brain injury (mTBI), which has been associated with neurodegenerative...
NIH-funded scientists have discovered that Parkinson’s disease increases the amount of “free” water in a particular brain area

NIH-funded scientists have discovered that Parkinson’s disease increases the amount of “free” water in a particular brain area. Image courtesy of David Vaillancourt, Ph.D., University of Florida.

News | Neuro Imaging | July 31, 2017
Scientists at the University of Florida have discovered a new method of observing the brain changes caused by Parkinson...
more healthcare providers and patients are choosing options such as Gamma Knife stereotactic radiosurgery
News | Radiation Therapy | July 31, 2017
Each year, up to 650,000 people who were previously diagnosed with various forms of cancer will develop brain...
"Residual Echo" of Ancient Humans May Hold Clues to Mental Disorders

MRI data shows (left) areas of the skull preferentially affected by the amount of Neanderthal-derived DNA and (right) areas of the brain’s visual system in which Neanderthal gene variants influenced cortex folding (red) and gray matter volume (yellow). Image courtesy of Michael Gregory, M.D., NIMH Section on Integrative Neuroimaging

News | Neuro Imaging | July 26, 2017
Researchers from the National Institute of Mental Health (NIMH) have produced the first direct evidence that parts of...
New York Hospital Finds Significant Cost Savings With Toshiba’s Aquilion One CT
News | Computed Tomography (CT) | July 25, 2017
In five years, Kaleida Health’s Stroke Care Center (SCC) at the Gates Vascular Institute in Buffalo, N.Y., has realized...
Radiotherapy Prior to Surgery Reduces Secondary Tumor Risk in Early-Stage Breast Cancer Patients
News | Radiation Therapy | July 24, 2017
Moffitt Cancer Center researchers launched a first-of-its-kind study comparing the long-term benefits of radiation...
Electronic Brachytherapy Comparable to Mohs Surgery in Early-Stage Non-Melanoma Skin Cancer Treatment
News | Brachytherapy Systems | July 20, 2017
July 20, 2017 — Rates of recurrence in early-stage non-melanoma skin cancer (NMSC) patients were virtually identical
Overlay Init